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Abstract The renin angiotensin system (RAS) has pro-
found effects on atherosclerosis development in animal
models, which is partially complimented by evidence in the
human disease. Although angiotensin II was considered to
be the principal effector of the RAS, a broader array of
bioactive angiotensin peptides have been identified that
have increased the scope of enzymes and receptors in the
RAS. Genetic interruption of the synthesis of these peptides
has not been extensively performed in experimental or
human studies. A few studies demonstrate that interruption
of a component of the angiotensin peptide synthesis
pathway reduces experimental lesion formation. The evi-
dence in human studies has not been consistent. Con-
versely, genetic manipulation of the RAS receptors has
demonstrated that AT1a receptors are profoundly involved
in experimental atherosclerosis. Few studies have reported
links of genetic variants of angiotensin II receptors to
human atherosclerotic diseases. Further genetic studies are
needed to define the role of RAS in atherosclerosis.
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Introduction
The development of atherosclerotic lesions is a chronic
disease that proceeds through complex biochemical and
cellular changes [1]. The proposed mechanistic basis for
many of the events in the initiation and maturation phases
of lesion formation has involved aberrant metabolism of
cholesterol transport. Indeed, we now have several decades
of evidence that dysfunctional cholesterol metabolism is a
major determinant of lesion development. However, more
recently, substantial data have accumulated using genetic
and pharmacologic approaches demonstrating a profound
role for the renin angiotensin system (RAS) in experimental
atherosclerosis. Although the RAS is a primary mediator of
blood pressure and fluid balance, neither of these effects is
the primary basis for the RAS to promote atherosclerosis.
The consistent experimental literature has been compli-
mented by a relatively uniform literature demonstrating a
role for the RAS in human atherosclerotic disease.
The classical RAS synthesis pathway consists of a
simple two-step enzymatic process in which angiotensino-
gen has 10 amino acids cleaved from the N terminus by
renin and a subsequent removal of two further amino acids
by angiotensin-converting enzyme (ACE) to yield the
bioactive octapeptide, angiotensin II (AngII). Although
the principal source of angiotensinogen, renin, and ACE
have been the liver, kidneys, and lungs, respectively, there
are evolving complexities of the location of these compo-
nents. There is also a growing appreciation that other
bioactive angiotensin peptides can be generated by more
recently recognized RAS enzymes such as aminopeptidases
and a homologue of ACE, termed ACE2. Therefore, it has
now been defined that the RAS generates a range of
bioactive peptides, some of which have direct antagonistic
effects to each other [2••].
The principal receptor mediating most of the described
effects of AngII is the AT1 receptor, which is a seven
transmembrane G protein–coupled receptor [3]. AT1 recep-
tors are expressed in most major organs. There is a highly
consistent literature regarding the role of AT1 receptors
mediating many of the physiologic and pathologic effects
A. Daugherty (*): A. Poduri: X. Chen: H. Lu:L. A. Cassis
Saha Cardiovascular Research Center, University of Kentucky,
BBSRB, Room B-243,
Lexington, KY 40536-0509, USA
e-mail: Alan.Daugherty@uky.edu
Curr Atheroscler Rep (2010) 12:167–173
DOI 10.1007/s11883-010-0109-4of AngII. AT1 receptors undergo a chromosomal duplica-
tion resulting in the expression of two closely related
subtypes that have been termed “a” and “b” in rodents.
These receptors have 96% sequence similarity and are
indistinguishable by pharmacologic approaches. The major-
ity of the sequence variations between the subtypes are in
the C-terminal intracellular region. Although poorly
defined, sequence differences in these intracellular regions
have the potential to mediate subtype-specific responses to
AngII through complex signaling pathways [4••]. The
predominance of AngII effects in rodents are via stimula-
tion of AT1a receptors, although effects such as aortic
contractions appear to be AT1b receptor-dependent [5].
AngII also stimulates AT2 receptors that are frequently
considered to antagonize the effects of AT1 receptor
stimulation. AT2 receptors are highly expressed in fetal
tissues, but the abundance of the receptor markedly declines
after birth. Unlike AT1 receptors, the functional consequen-
ces of AngII stimulation of AT2 receptors have generated an
inconsistent literature in which effects are generally modest.
In animal studies, the predominance of the studies to
determine a link of the RAS to atherosclerosis has been
performed using genetically engineered mice to change
receptor expression. This has also been combined with bone
marrow transplantation to elucidate the role of a specific
AngII receptor on cells on atherosclerosis. The experimental
studies have the advantage of being able to retrieve
atherosclerotic tissues to enable a direct measurement of
size and characteristics of lesions. Obviously, studies in
humans are not able to directly interrogate atherosclerotic
tissues. Although imaging modalities are improved, insight-
ful approaches have not been applied to the genetics of the
RAS in the human disease. Therefore, a caveat of comparing
experimental to human studies is the latter predominantly use
indirect end points of atherosclerosis-associated diseases such
as acute myocardial infarction and stroke.
Genetic Determinants of Angiotensin Peptide
Biosynthesis on Atherosclerosis
Experimental Studies
There are genetically engineered mice that manipulate
many of the components of the classic RAS. These include
deficiencies of angiotensinogen, renin, and ACE. Unfortu-
nately, deficiency of any of these proteins leads to the
generation of mice that have similar profound renal
deficiencies. Many of the offspring die shortly after birth.
However, the pups can be rescued by subcutaneous
injection of saline in the first 14 days after birth. Following
rescue at the early pup stage, mice with whole body
deficiency of angiotensinogen, renin, or ACE have persis-
tent kidney abnormalities and high urine output but have
comparable life span as wild-type mice without any further
intervention.
The genetic manipulations of the RAS in atherosclerosis
have been performed in mice, most commonly in those that
lack either apolipoprotein E (apoE) or low-density lipo-
protein LDL receptors [6]. Currently, no atherosclerosis
studies have been performed using mice with whole body
deficiencies of angiotensinogen or renin. However, one
study has used genetic deficiency of renin to determine the
contribution of this enzyme activity in bone marrow–
derived cells to lesion development. Bone marrow–derived
stem cells were harvested from renin -/- mice and
repopulated into irradiated LDL receptor -/- mice [7•].
LDL receptor -/- mice repopulated with renin -/- bone
marrow-derived cells had dramatically reduced lesion size
after 3 months of feeding a saturated fat–enriched diet,
compared with those repopulated with strain-matched, age-
matched, and gender-matched cells that were wild-type for
renin. There was no indication that the absence of renin in
bone marrow–derived cells had any effect on the activation
status of the systemic RAS. The lack of effect on the
systemic RAS in these studies suggests that bone marrow–
derived cells provide renin for local synthesis of angioten-
sin peptides within the artery in the development of
atherosclerosis.
Initial studies investigated the role of ACE using
heterozygous deficient mice bred into an apoE +/- back-
ground [8]. No effects were noted on lesion size or on the
chemical or cellular content of the lesions. A subsequent
study used a variant named ACE.2, which expresses a
soluble truncated form of the somatic form of the enzyme
that is not cell tethered. Heterozygous ACE.2 (ACE +/2)
mice on an apoE -/- background had greatly reduced
atherosclerotic lesion size [9]. The authors were only able
to generate two mice that were homozygous (ACE 2/2) for
the ACE.2 variant, which anecdotally had profoundly
reduced lesion size. A more recent study was able to
generate sufficient numbers of ACE 2/2 mice in an apoE -/-
background to enable a statistically meaningful experiment
[10]. Weiss et al. [10] demonstrated that homozygous
ACE.2 mice had large reductions in atherosclerotic lesion
size of apoE -/- mice fed either a normal-fat or a saturated
fat–enriched diet. This group also studied atherosclerosis in
apoE -/- mice carrying the ACE.3 variant. This variant has
ACE expression that is restricted to the liver and kidney,
with which the mice have undetectable ACE expression in
the aorta but normal blood pressure. However, ACE 3/3
mice did not show a reduction of atherosclerosis compared
with wild-type controls. ACE protein has been detected in
several cell types within experimental and human athero-
sclerotic lesions [11, 12]. Therefore, although ACE is
present in lesions, the authors concluded that the locally
168 Curr Atheroscler Rep (2010) 12:167–173expressed enzyme was not an absolute requirement for
atherosclerosis development.
Table 1 summarizes the effects of genetic manipulations
of components of angiotensin synthesis on development of
atherosclerosis in mice. There are many publications that
have used pharmacologic inhibition of renin or ACE to
demonstrate a role for these enzymes in the development of
experimental atherosclerosis [13, 14]. However, there is a
paucity of studies using genetic manipulations of the
enzymes involved in angiotensin peptide synthesis on
atherosclerosis development. Given the adverse effect of
the whole body deficiencies of these enzymes, this field
would be greatly enhanced by the availability of conditional
knockout mice for either of these enzymes or their unique
precursor, angiotensinogen. The availability of such mice
would permit cell-specific and temporally controlled
genetic deficiencies to be induced without attendant renal
defects. Such mice would provide insight into the origin of
the angiotensin peptides in lesion formation.
Human Studies
Of the three major proteins involved in the synthesis of
angiotensin peptides, angiotensinogen, renin, and ACE,
genes encoding for angiotensinogen and ACE have been
investigated extensively to link genetic determinants of the
RAS to atherosclerotic diseases in humans. A large number
of single nucleotide polymorphisms (SNPs) have been
described in the angiotensinogen gene located on chromo-
some 1. The most studied is the angiotensinogen M235T
polymorphism, which consists of a nucleotide substitution
in exon 2 that leads to the replacement of methionine to
threonine at position 235 in the amino acid sequence, which
has been proposed as a candidate influencing the predis-
position to atherosclerotic diseases in humans [15].
Although there have been studies to confirm this relation-
ship [16], these have not been consistent [17, 18•].
The most frequently studied polymorphism of the ACE
gene on chromosome 17 is the insertion/deletion (I/D). This
polymorphism is based on the presence or absence of a
250–base pair element located within intron 16 [19].
Because the difference is present in an intronic sequence, it
seems unlikely to have functional consequences. Rather, it
was suggested that the I/D polymorphism has a linkage
disequilibrium to a region controlling ACE expression. A
strong association has been noted between the ACE I/D gene
polymorphism and activity of this enzyme in both blood and
tissues. The I/I genotype was initially proposed to be
protective because it is associated with greatly reduced ACE
activity (approximately half) compared with D/D carriers.
The association of the ACE I/D polymorphism with the
atherosclerosis-based disease was initially based on a multi-
center, case-controlled study [20]. Petrovic and Peterlin
[21] summarized earlier studies that investigated the link
between I/D polymorphism and atherosclerosis-based dis-
eases. Although some earlier studies confirmed the associ-
ation between ACE I/D polymorphism and coronary artery
disease, the first prospective study on a large sample size
(n=3590) failed to show any association [22]. Since the
reviews of Petrovic and Peterlin [21] and Sayed-Tabatabaei
et al. [23], subsequent studies have not clarified the link
between ACE polymorphisms and atherosclerotic-based
diseases. More recent studies have focused on the potential
for ACE polymorphisms to predict coronary artery disease
or determine whether the information provides any benefit
to optimize therapeutic strategies, but they have failed to
quell the inconsistencies in the literature. Furthermore, a
recent meta-analysis of 58 studies of ACE I/D poly-
morphism on the response to therapeutic approaches for
coronary artery disease concluded that the identification of
this polymorphism provided no benefit to define clinical
decisions [24]. Overall, despite the large number of studies
to define the association of ACE polymorphisms and
coronary artery disease, the lack of consistency indicates
that such information will have little general use in
predicting the onset and severity of the disease or providing
useful information to personalize therapies.
Although polymorphisms of a single component of the
RAS have not generated consistently insightful data, more
recent studies have provided evidence that a combination of
genotype variants of the RAS genes may be a more
powerful determinant of coronary artery diseases [25, 26].
Manipulation Model Gender Atherosclerosis effect Study
Whole body manipulation
ACE +/- apoE +/- Male and female No effect Krege et al. [8]
ACE +/2 apoE -/- Male Decrease Hayek et al. [9]
ACE 2/2 apoE -/- Male Decrease (n=2) Hayek et al. [9]
Decrease Weiss et al. [10]
ACE 3/3 apoE -/- Male No effect Weiss et al. [10]
Bone marrow transplantation
Renin -/- LDL receptor -/- Male Decrease Lu et al. [7•]
Table 1 Effects of genetic
manipulations of components
of angiotensin peptide
synthesis on development of
atherosclerosis in mice
ACE angiotensin-converting
enzyme, LDL low-density
lipoprotein
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on Atherosclerosis
Experimental Studies
Because the predominance of AngII effects in mice appears to
be mediated via AT1a receptors, most of the genetic studies
have used mice that are depleted of this receptor (Table 2).
There has been a great consistency in the marked reduction in
atherosclerosis in AT1a receptor -/- mice that are hyper-
cholesterolemic due to deficiency of either apoE or LDL
receptors combined with diet enriched in saturated fat [11,
27–30]. AT1a receptor deficiency also completely attenuated
atherosclerosis in LDL receptor -/- mice augmented by AngII
infusion [31, 32]. Furthermore, AT1a receptor deficiency also
reduced atherosclerosis in diabetic apoE -/- mice [33]. The
reduced atherosclerosis in AT1a receptor deficient mice has
been consistent across all reports, in both genders, at all ages
studied, and in different vascular beds that have been studied.
The atherosclerosis literature is replete with conflicting data
for the effect of genetic manipulations. Therefore, the
consistency of the literature on AT1a receptor deficiency
reducing atherosclerosis is both unusual and noteworthy.
Because most of the atherosclerosis mouse models are
generated by dysfunctional cholesterol metabolism, it is
surprising that deletion of AT1a receptors has such a large
and consistent effect on lesion reduction. The resolution of
this apparent paradox may be that the hypercholesterolemic
state is associated with a marked augmentation of the RAS in
terms of circulating proteins involved in the synthesis and
secretion of angiotensin peptides [11]. The protective effect
of AT1a receptor deficiency has been associated with
changes in several measurements, including decreased oxi-
dant stress and metalloproteinase expression and enhanced
endothelial function. However, it has not been defined if
these changes are a cause or consequence of the decreased
atherosclerosis [27, 29]. Blood pressure changes have also
been inconsistent in hypercholesterolemic AT1a receptor–
deficient mice [11, 27]. Nevertheless, blood pressure per se
does not appear to be a major factor in the development of
atherosclerosis in mouse models of the disease [13].
The effect of AT1a receptors on atherosclerosis has also
been studied using bone marrow transplantation. It has
primarily been used to define the role of AT1a receptor
expression on leukocytes that infiltrate during lesion
development, although this technique has the potential to
also influence other cell types that originate from bone
marrow. Unlike the uniform demonstration of whole body
AT1a receptor deficiency decreasing atherosclerosis, the
literature using bone marrow transplantation has produced
Table 2 Effects of genetic manipulations of angiotensin II receptors on development of atherosclerosis in mice
Receptor
deficiency
Model Gender Atherosclerosis effect Study
Whole body deficiency
AT1a LDL receptor -/- Male and
female
Decrease Daugherty et al. [11]
apoE -/- Male Decrease Wassmann et al. [27]
Decrease Li et al. [28]
Decrease Tomono et al. [30]
Decrease Eto et al. [29]
Diabetic apoE-/- Decrease Ihara et al. [33]
AT2 LDL receptor -/- Male and
female
No effect Daugherty et al. [11]
apoE-/- Male Increase Iwai et al. [39]
No effect on size, but composition change Sales et al. [38]
Diabetic apoE-/- Decrease Koitka et al. [37]
Bone marrow transplantation
AT1a LDL receptor -/-; AngII
infused
Male No effect in AT1aR -/-; modest decrease in +/+ Cassis et al. [31]
apoE -/-; AngII infused No effect in AT1aR -/-; modest decrease in +/+ Koga et al. [35]
LDL receptor -/- No effect Lu et al. [7•]
apoE -/- Decrease Fukuda et al. [32]
Decrease Tsubakimoto et al.
[34]
Increase Kato et al. [36]
AngII angiotensin II, apoE apolipoprotein E, LDL low-density lipoprotein
170 Curr Atheroscler Rep (2010) 12:167–173inconsistent results. AT1a receptor deficiency in bone
marrow–derived cells has been demonstrated to attenuate
[32, 34], have no effect [7, 31, 35], or increase athero-
sclerosis [36] in hypercholesterolemic mice, either induced
by hypercholesterolemia alone or augmented with AngII
infusion. The basis for this inconsistency is not readily
apparent. Another approach to determine the role of the
AT1a receptor expression in specific cell types is the use of
Cre-lox technology to develop deficiencies that can be both
cell specific and inducible at specific time intervals.
However, there are currently no reports that have used
conditional genetic deficiencies of AT1a receptors to define
the cellular components that are stimulated by AngII or
hypercholesterolemia to augment atherosclerosis.
As described above, AngII stimulation of AT2 receptors
is commonly considered to exert opposite effects to AngII
stimulation of AT1 receptors. Contrary to the consistent
reductions of atherosclerosis in AT1a receptor–deficient
mice, genetically engineered deficiency of AT2 receptors
has generated a range of responses. The changes of
atherosclerosis in hypercholesterolemic AT2 receptor–defi-
cient mice cover the entire spectrum of decreases [37], no
effect [11], no effect on size but changes in composition
[38], or increases [39] in lesion formation.
Overall, the effects of the genetically engineered whole
body deficiency of AT1a receptors have been both striking in
the magnitude of the effects and consistent in reports from
many laboratories. This contrasts sharply with the literature
to define the cellular location of the AT1a receptors involved
in the development of atherosclerosis. It also contrasts
sharply with genetic studies on AT2 receptors. There is no
obvious explanation for this inconsistent literature.
Human Studies
The relevance of angiotensin receptors in atherosclerosis has
been observed in humans in a limited number of gene
association human studies. As noted above, the AT1 receptor
located on chromosome 3 is thought to mediate most of the
effects of AngII [40]. One of the most common genetic
variants is the A1166C SNP located in the 3’ UTR region of
the AT1 receptor gene. The CC mutant genotype has been
associated with increased risk of myocardial infarction,
coronary artery stenosis, and carotid atherosclerosis [41,
42]. This polymorphism was also associated with increased
total plasma cholesterol concentrations and influenced the
risk for essential hypertension [43]. In Chinese men, the
combined effects of all functional genetic variants present in
this gene were associated with increased risk of myocardial
infarction [44]. In addition, combination of genetic
variants of ACE I/D along with AT1 receptor A1166C
polymorphism have been predicted as powerful determi-
nants for atherosclerosis. Conversely, numerous studies
havealsodemonstratednoassociationofthispolymorphism
with atherosclerosis [45–47]. Another polymorphism in
exon 5 of the AT1 receptor gene, which is conversion of C
to T at 537 position, has been found to be not associated
with atherosclerosis [48].
The AT2 receptor gene is located on the X chromosome.
A common polymorphism of AT2 receptors, -1332 G/A, is
present in the promoter region but has not been found to be
associated with premature coronary artery disease [49].
Recently, another polymorphism in the AT2 receptor gene
has been reported, which is A1675G located in intron 1.
This genetic variant has been associated with the increased
severity of atherosclerosis, especially in hypertensive males
[50]. Collectively, there have been inconsistent reports
obtained from population-based studies. As with the gene
association studies in proteins of angiotensin peptide
synthesis, they have yielded relatively little to providing
insight into the pathology of atherosclerosis.
Conclusions
The role of the RAS has been explored extensively in
experimental atherosclerosis using pharmacologic and
genetic approaches. Although the literature is unusually
consistent in defining a role of the RAS in atherosclerosis,
specific mechanistic insights are missing or inconsistent.
Genetic approaches would be the most definitive approach
to the elucidation of these deficiencies of information.
Unlike the experimental studies, there is scant information
of the role of genetic determinants of the RAS in human
atherosclerotic-associated diseases.
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